Employing a workforce of 1850 people worldwide, the French Exail group strengthened itself with the integration of the photonics company Leukos, which specializes in advanced laser sources for metrology, spectroscopy, and imaging applications. Leukos brings two decades of expertise in developing high-tech products, including pulsed microlasers, supercontinuum laser sources, and ultrafast fiber lasers.

Expanding its technological capabilities in photonics, this acquisition marks a significant milestone for Exail. By combining Leukos’ advanced technologies with Exail’s expertise in specialty fibers, modulation, micro-optical assemblies, and quantum systems, the group enhances its product offerings and expands its solutions to address new markets, including biophotonics and microelectronics. Leukos will operate as a subsidiary of Exail, retaining its product portfolio and branding to ensure continuity for customers and partners.

“This is a great opportunity for Leukos to become part of Exail. With the added value of Exail’s proven technologies, we see new directions of innovation focused on developing unique products. Joining Exail will also accelerate the commercial development of our laser technologies and laser-based systems,” said Guillaume Huss, CEO of Leukos.

“We are thrilled to welcome Leukos into the Exail family. This acquisition perfectly aligns with our photonics strategy by broadening our technological portfolio, accelerating innovation, and strengthening our global reach. Together, we will combine our expertise to deliver cutting-edge solutions to our scientific and industrial customers worldwide, while supporting Leukos in scaling its unique technologies to new markets,” said Fabien Napolitano, CEO of Exail.

Leukos was created in 2006 as a spin-off from the XLIM research institute, a joint research unit from CNRS and the University of Limoges. The company was founded by pioneers of supercontinuum generation to develop brand new compact supercontinuum lasers based on their expertise in nonlinear optics.